Table 2.
Summary of diagnostic accuracy studies
Country | Type of test | Source of assay | Total cases | Antigenic strain | Positivity cutoff titer | Antibody target | Positivity criteria | Cutoff justification | Reference |
---|---|---|---|---|---|---|---|---|---|
Israel | IFA | NA | 23 | NA | ≥ 1:100 | Whole | Single titer | NA | 74 |
Lao PDR | IFA | Australian Rickettsial Reference Laboratory, Victoria, Australia | 1030 | Wilmington | ≥ 1:400 | IgM | Single titer | 17 | 75 |
≥ 4-fold increase | IgM and IgG | Only 4-fold | |||||||
IFA | NA | 50 | Wilmington | ≥ 1:400 | Whole | Both | 17 | 76 | |
≥ 4-fold increase | Whole | ||||||||
Peru, United States, Somalia, and Indonesia | IFA | NA | 60 | Wilmington | ≥ 1:128 | IgG | Single titer | NA | 8 |
Russia, Peru, and Burundi | IFA | Dynatech Laboratories Ltd, UK | 308 | Wilmington | ≥ 1:128 | IgG | Single titer | 25,26 | 13 |
IFA = immunofluorescence assay.